cardiovascular system News
-
21 Jun 2010: NIH-supported study finds novel pathway May open doors for new blood pressure treatments
Researchers have found that increasing certain proteins in the blood vessels of mice, relaxed the vessels, lowering the animal’s blood pressure. The study provides new avenues for research that may lead to new treatments for hypertension. "The paper demonstrates that cytochrome P450 plays an important role in the management of high blood pressure, a disease of enormous public health ...
-
Flosonics Medical selected as a winner of Vale’s COVID-19 Challenge
The company was one of two Northern Ontario organizations selected to receive financial support aimed at propelling innovative COVID-19 solutions into the marketplace Flosonics Medical was one of two Northern Ontario organizations selected as a winner of Vale’s 2020 COVID-19 Challenge. The challenge, which was launched in Canada on April 3, 2020, aimed to propel innovative COVID-19 ...
-
Soundbite Medical Solutions Announces Issuance of Two New U.S. Patent Further Expanding Coverage of its Shock Wave Technology
Soundbite Medical Solutions Inc. (SBMS), a medical device company leveraging its proprietary shock wave technology for the interventional treatment of calcific occlusive peripheral and coronary arterial diseases, today announced that the United States Patent and Trademark Office has issued two additional US patents. Patent No. 11,419,619, entitled “Method and system for treating ...
-
Kardiolytics’ VCAST Technology Offers Non-Invasive and Safe Solution for Functional Evaluation of Coronary Disease, According to Recent Study in Cardiovascular Engineering and Technology
Our latest publication in Cardiovascular Engineering and Technology showcases the feasibility and functionality of our VCAST technology, a patented, AI-based medical system developed for non-invasive, clinical quantitative and qualitative analysis of CT-scan data, to assess the hemodynamic significance of coronary artery atherosclerotic stenosis. Using a ...
-
Bisphenol A: EFSA consults on assessment of risks to human health
EFSA is launching a public consultation on its draft assessment of the human health risks posed by exposure to bisphenol A (BPA). The Authority has undertaken a comprehensive review of scientific literature and previous risk assessments from expert bodies on BPA. All stakeholders and interested parties are invited to comment on the document through an online public consultation that runs until ...
-
Magnolia Medical Appoints Industry Veteran, Joseph Bishop, as the Senior Vice President of Operations and Product Development
Magnolia Medical Technologies, Inc., inventors of Steripath, the only FDA 510(k)-cleared device platform indicated to reduce blood culture contamination for sepsis testing,1 today announced the addition of Joseph Bishop to the executive leadership team as Senior Vice President of Operations and Product Development. Mr. Bishop brings extensive and diverse medical device experience to Magnolia ...
-
New Offerings Released at Alfa Chemistry: Isoquinoline Alkaloids, Pyridine Alkaloids, and Phenylethylamine Alkaloids
Known for their extraordinarily antiparasitic, antiplasmodial, anticorrosive, antioxidative, antibacterial, anti-HIV, and insecticidal activities, alkaloids have found wonderful use in the pharmaceutical and medicinal filed as well as the human food and drink industry. To cater to the growing market demand for such type of chemicals, Alfa Chemistry recently announced a decision to open a new ...
-
Invizius attracts £2.75m Pre-Series A investment
Invizius, the University of Edinburgh spin-out whose technology could help reduce the high death rates amongst dialysis patients, has raised £2.75m from a consortium of investors. The funding round was led by Mercia and included Downing Ventures, the University’s Old College Capital fund and the Scottish Investment Bank. The latest investment will support the company as it conducts ...
-
Amsel Medical Corporation Announces First-In-Man Clinical Use of the Amsel Occluder Device at NYU Langone Medical Center
Amsel Medical Corporation Announces Industry Exhibit of the Amsel Occluder Device at the 2017 Veith Symposium (NY) November 14-18, 2017. The Amsel Occluder Device is intended for use in open general surgery procedures on tubular structures or vessels wherever a metal ligating clip is indicated and within the size range of 2.0mm to 7.0mm diameter. Amsel Medical Corporation today ...
-
Invizius secures £0.5m investment
A spinout company whose technology could save the lives of thousands of dialysis patients has secured £500,000 from Mercia Asset Management, in the first investment deal since Mercia’s partnership with the University of Edinburgh was announced in November 2017. Invizius stems from years of research by Invizius co-founder, Dr Andy Herbert and his team, who believe they have ...
-
T,C&A Lab Declares Capability of Biomedical Materials Testing
Since the last few decades, biomedical materials have been extensively used in a lot of medical applications, such as tissue scaffolds, wound care, regenerative dentistry, bone graft, implantable devices and cosmetic surgery. Earlier this month, T,C&A Lab, a branch of Alfa Chemistry, announces to provide biomedical material testing service for customers worldwide who would like to ensure ...
-
Cyanotech Donates Protein Powder and Medical Supplies to Local Hospitals
Cyanotech®, (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health products, has donated over 700 bottles of their Hawaiian Spirulina® Protein Shake and personal protective equipment (PPE) to two Hawaii Island hospitals. Cyanotech grows and produces Hawaiian Spirulina, a powerful superfood with immune boosting benefits and BioAstin® Hawaiian ...
-
SaNOtize Obtains Health Canada Approval to Commence Phase II Trial for Potential COVID-19 Therapy
SaNOtize Research and Development Corporation (“SaNOtize” or “the company”) today announced that it has been granted approval by Health Canada to conduct a multiCentre Phase II prevention and efficacy trial for a front-line antiviral prevention and early treatment for use against COVID-19. SaNOtize also announced that new tests conducted by the Institute for Antiviral ...
-
BioCardia Announces FDA Approval of Its IND for NK1R+ Mesenchymal Stem Cells for the Treatment of Patients Recovering from Acute Respiratory Distress due to COVID-19
BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) application for BCDA-04, a proprietary allogeneic mesenchymal cell (MSC) population that is Neurokinin-1 receptor positive ...
-
Robocath bolsters Strategic Committee with appointment of Chantal Le Chat as independent member
Chantal boasts 35 years of skill and know-how built up while working a range of posts at imaging major player GE Healthcare. Over the last six years, she has occupied key strategic roles in the company’s Interventional Division, including Global GM. Her duties as an independent member of the Strategic Committee will include supporting the governance of Robocath. She will use her extensive ...
By Robocath
-
Robocath successfully carries out Europe’s first remote robotic-assisted coronary angioplasty
Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, today announces the successful completion of the first remote robotic-assisted coronary angioplasty in Europe. The procedure was carried out by Prof. Eric Durand and Prof. Rémi Sabatier at the Rouen Medical Training Center and Caen University Hospital in ...
By Robocath
-
Longeveron Announces Publication of Lomecel-B Phase 2b Trial Design in Journal of Frailty and Aging
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced today publication of the design and rationale from its recently completed Phase 2b aging frailty clinical trial with Lomecel-B in the Journal of Frailty and Aging. This peer-reviewed ...
-
EU scientific committee looks for mercury alternatives
April saw EU scientists actively seeking advice on possible alternatives to a pollutant that threatens the health of millions, from humans, animals to ecosystems. The EU’s Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) is currently undergoing research into the possible substitutes to mercury-containing sphygmomanometers. Under a 2007 directive (Directive 2007/51/EC) ...
-
Biomedical Company Gedeon Richter Partners with Health Education Platform Skrinings to Deliver Global, No-Cost Contraceptive Education
Women’s health platform Skrinings.lv announced today that it has partnered with multinational pharmaceutical company Gedeon Richter to launch a completely private educational platform that empowers people to make informed decisions about contraception and other birth control options. In the first two months of operations, more than 1,700 women across Northern and Western Europe have taken ...
By Longenesis
-
U.S. EPA Awards Grant of Nearly $650,000 to University of Calif. Davis
The U.S. Environmental Protection Agency (EPA) today announced a research grant of nearly $650,000 was awarded to the University of Calif. Davis to investigate the effect of environmental agents on thyroid hormones and modeling how the chemicals affect organism health. The grant was part of almost $11 million awarded to eight universities through EPA’s Science to Achieve Results (STAR) ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you